{"DataElement":{"publicId":"6597006","version":"1","preferredName":"Hematopoietic and Lymphoid Cell Neoplasm First Relapse World Health Organization Classification Subtype","preferredDefinition":"Text term that represents the subtype of first relapse according to World Health Organization (WHO) classification of tumors of hematopoietic and lymphoid tissue.","longName":"6591145v1.0:6594394v1.0","context":"OCG","contextVersion":"1","DataElementConcept":{"publicId":"6591145","version":"1","preferredName":"Hematopoietic and Lymphoid Cell Neoplasm First Recurrent Disease Diagnosis World Health Organization Subtype","preferredDefinition":"A cancer of the blood or bone marrow, such as leukemia or lymphoma._Preceding all others in time or space or degree._The return of a disease after a period of remission._The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation._A United Nations agency established to coordinate international health activities and to help governments improve health services._A group forming a type within a larger type.","longName":"4057012v1.0:6591143v1.0","context":"OCG","contextVersion":"1","ObjectClass":{"publicId":"4057012","version":"1","preferredName":"Hematopoietic and Lymphoid Cell Neoplasm","preferredDefinition":"A cancer of the blood or bone marrow, such as leukemia or lymphoma.","longName":"C27134","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hematopoietic and Lymphoid Cell Neoplasm","conceptCode":"C27134","definition":"A neoplasm that arises from hematopoietic and lymphoid cells. Representative examples include myeloproliferative neoplasms, myelodysplastic syndromes, leukemias, Hodgkin lymphomas, and non-Hodgkin lymphomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"EF7A7F80-F26C-BDD3-E040-BB89AD4354F1","latestVersionIndicator":"Yes","beginDate":"2014-01-08","endDate":null,"createdBy":"ABRAHAML","dateCreated":"2014-01-08","modifiedBy":"ONEDATA","dateModified":"2014-01-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6591143","version":"1","preferredName":"First Recurrent Disease Diagnosis World Health Organization Subtype","preferredDefinition":"Preceding all others in time or space or degree.:The return of a disease after a period of remission.:The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation.:A United Nations agency established to coordinate international health activities and to help governments improve health services.:A group forming a type within a larger type.","longName":"6591143v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"First","conceptCode":"C25509","definition":"Preceding all others in time or space or degree.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Recurrent Disease","conceptCode":"C38155","definition":"The return of a disease after a period of remission.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Diagnosis","conceptCode":"C15220","definition":"The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"World Health Organization","conceptCode":"C75419","definition":"A United Nations agency established to coordinate international health activities and to help governments improve health services.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Subtype","conceptCode":"C25696","definition":"A group forming a type within a larger type.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7D019C93-745F-579A-E053-F662850A3C44","latestVersionIndicator":"Yes","beginDate":"2018-12-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-12-14","modifiedBy":"ONEDATA","dateModified":"2018-12-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"TARGET:Therapeutically Applicable Research to Generate Effective Treatments","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7D019C93-7470-579A-E053-F662850A3C44","latestVersionIndicator":"Yes","beginDate":"2018-12-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-12-14","modifiedBy":"COOPERM","dateModified":"2019-01-16","changeDescription":"Created for CDE Request 12.13.18 mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6594394","version":"1","preferredName":"ALAL WHO Classification Type","preferredDefinition":"Something distinguishable as an identifiable class based on common qualities.","longName":"6594394v1.0","context":"OCG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"15","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"ALL","valueDescription":"Acute Lymphoblastic Leukemia","ValueMeaning":{"publicId":"3322383","version":"1","preferredName":"Acute Lymphoblastic Leukemia","longName":"3322383","preferredDefinition":"Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Lymphoblastic Leukemia","conceptCode":"C3167","definition":"Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B36DFA8A-BB5D-6AE7-E040-BB89AD432073","latestVersionIndicator":"Yes","beginDate":"2011-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7D410CC5-5DBF-161E-E053-F662850AE1EA","beginDate":"2018-12-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-12-17","modifiedBy":"ONEDATA","dateModified":"2018-12-17","deletedIndicator":"No"},{"value":"AML","valueDescription":"Acute Myeloid Leukemia","ValueMeaning":{"publicId":"4263972","version":"1","preferredName":"Acute Myeloid Leukemia","longName":"4263972","preferredDefinition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise categorized. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia","conceptCode":"C3171","definition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F63DCAA0-1110-5D4B-E040-BB89AD432C9C","latestVersionIndicator":"Yes","beginDate":"2014-04-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-04","modifiedBy":"KUMMEROA","dateModified":"2022-05-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7D410CC5-5DC9-161E-E053-F662850AE1EA","beginDate":"2018-12-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-12-17","modifiedBy":"ONEDATA","dateModified":"2018-12-17","deletedIndicator":"No"},{"value":"T-ALL","valueDescription":"T Acute Lymphoblastic Leukemia","ValueMeaning":{"publicId":"4263973","version":"1","preferredName":"T Acute Lymphoblastic Leukemia","longName":"4263973","preferredDefinition":"Acute lymphoblastic leukemia of T-cell origin.  It comprises about 15% of childhood cases and 25% of adult cases.  It is more common in males than females.  (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"T Acute Lymphoblastic Leukemia","conceptCode":"C3183","definition":"Acute lymphoblastic leukemia of T-cell origin.  It comprises about 15% of childhood cases and 25% of adult cases.  It is more common in males than females.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F63DCAA0-1133-5D4B-E040-BB89AD432C9C","latestVersionIndicator":"Yes","beginDate":"2014-04-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-04","modifiedBy":"KUMMEROA","dateModified":"2023-12-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7D410CC5-5DDD-161E-E053-F662850AE1EA","beginDate":"2018-12-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-12-17","modifiedBy":"ONEDATA","dateModified":"2018-12-17","deletedIndicator":"No"},{"value":"B-ALL","valueDescription":"B Acute Lymphoblastic Leukemia","ValueMeaning":{"publicId":"4263974","version":"1","preferredName":"B Acute Lymphoblastic Leukemia","longName":"4263974","preferredDefinition":"The most frequent type of acute lymphoblastic leukemia.  Approximately 75% of cases occur in children under six years of age.  This is a good prognosis leukemia.  In the pediatric age group the complete remission rate is approximately 95% and the disease free survival rate is 70%.  Approximately 80% of children appear to be cured.  In the adult age group the complete remission rate is 60-85%.  (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"B Acute Lymphoblastic Leukemia","conceptCode":"C8644","definition":"The most frequent type of acute lymphoblastic leukemia.  Approximately 75% of cases occur in children under six years of age.  This is a good prognosis leukemia.  In the pediatric age group the complete remission rate is approximately 95% and the disease free survival rate is 70%.  Approximately 80% of children appear to be cured.  In the adult age group the complete remission rate is 60-85%.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F63DCAA0-1156-5D4B-E040-BB89AD432C9C","latestVersionIndicator":"Yes","beginDate":"2014-04-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-04","modifiedBy":"KUMMEROA","dateModified":"2023-12-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7D410CC5-5DF1-161E-E053-F662850AE1EA","beginDate":"2018-12-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-12-17","modifiedBy":"ONEDATA","dateModified":"2018-12-17","deletedIndicator":"No"},{"value":"JMML","valueDescription":"Juvenile Myelomonocytic Leukemia","ValueMeaning":{"publicId":"2838584","version":"1","preferredName":"Juvenile Myelomonocytic Leukemia","longName":"2838584","preferredDefinition":"A myelodysplastic/myeloproliferative disease of childhood that is characterized by proliferation principally of the granulocytic and monocytic lineages.  Myelomonocytic proliferation is seen in the bone marrow and the blood.  The leukemic cells may infiltrate any tissue, however liver, spleen, lymph nodes, skin, and respiratory tract are the most common sites of involvement.  The prognosis is usually poor.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Juvenile Myelomonocytic Leukemia","conceptCode":"C9233","definition":"A clonal myeloid disorder of childhood previously classified as myelodysplastic/myeloproliferative neoplasm. It is characterized by the presence of monocytic proliferation in peripheral blood, less than 20% blasts in bone marrow and peripheral blood, splenomegaly, and the absence of BCR-ABL1 fusion. Almost all patients carry mutations of the RAS pathway.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A51A25-5942-CA49-E040-BB89AD435D3A","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"KUMMEROA","dateModified":"2023-09-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7D410CC5-5E05-161E-E053-F662850AE1EA","beginDate":"2018-12-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-12-17","modifiedBy":"ONEDATA","dateModified":"2018-12-17","deletedIndicator":"No"},{"value":"Ph+","valueDescription":"Mixed Phenotype Acute Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1","ValueMeaning":{"publicId":"5577814","version":"1","preferredName":"Mixed Phenotype Acute Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1","longName":"5577814","preferredDefinition":"A rare mixed phenotype acute leukemia in which the blasts also carry the translocation t(9;22)(q34.1;q11.2) by karyotypic analysis or the BCR-ABL1 translocation by FISH or PCR.  The prognosis is usually unfavorable.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mixed Phenotype Acute Leukemia with BCR-ABL1 Fusion","conceptCode":"C82192","definition":"A rare mixed phenotype acute leukemia in which the blasts carry the chromosomal translocation t(9;22)(q34.1;q11.2) that results in BCR-ABL1 gene fusion. The prognosis is usually unfavorable.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"416EFFB6-E49B-65FA-E053-F662850A1146","latestVersionIndicator":"Yes","beginDate":"2016-11-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-11-16","modifiedBy":"COOPERM","dateModified":"2018-12-17","changeDescription":"Updated definition and VM Long Name_ghd_11.16.16","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7D410CC5-5E19-161E-E053-F662850AE1EA","beginDate":"2018-12-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-12-17","modifiedBy":"ONEDATA","dateModified":"2018-12-17","deletedIndicator":"No"},{"value":"AUL","valueDescription":"Acute Undifferentiated Leukemia","ValueMeaning":{"publicId":"3322385","version":"1","preferredName":"Mixed Phenotype Acute Leukemia with BCR-ABL1 Fusion","longName":"3322385v1.00","preferredDefinition":"A rare mixed phenotype acute leukemia in which the blasts carry the chromosomal translocation t(9;22)(q34.1;q11.2) that results in BCR-ABL1 gene fusion. The prognosis is usually unfavorable.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mixed Phenotype Acute Leukemia with BCR-ABL1 Fusion","conceptCode":"C82192","definition":"A rare mixed phenotype acute leukemia in which the blasts carry the chromosomal translocation t(9;22)(q34.1;q11.2) that results in BCR-ABL1 gene fusion. The prognosis is usually unfavorable.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B36DFA8A-BB97-6AE7-E040-BB89AD432073","latestVersionIndicator":"Yes","beginDate":"2011-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"KUMMEROA","dateModified":"2024-01-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7D410CC5-5E2E-161E-E053-F662850AE1EA","beginDate":"2018-12-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-12-17","modifiedBy":"ONEDATA","dateModified":"2018-12-17","deletedIndicator":"No"},{"value":"MLL","valueDescription":"Mixed Phenotype Acute Leukemia with t(v;11q23.3); KMT2A Rearranged","ValueMeaning":{"publicId":"5577812","version":"1","preferredName":"Mixed Phenotype Acute Leukemia with t(v;11q23.3); KMT2A Rearranged","longName":"5577812","preferredDefinition":"A rare mixed phenotype acute leukemia in which the blasts also carry a translocation (v; 11q23.3) involving the KMT2A gene. The prognosis is usually unfavorable.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mixed Phenotype Acute Leukemia with KMT2A Rearrangement","conceptCode":"C82203","definition":"A rare mixed phenotype acute leukemia in which the blasts carry a translocation between the KMT2A gene at 11q23.3 and another gene partner. The prognosis is usually unfavorable.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"416EFFB6-E475-65FA-E053-F662850A1146","latestVersionIndicator":"Yes","beginDate":"2016-11-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-11-16","modifiedBy":"COOPERM","dateModified":"2018-12-17","changeDescription":"Update definition and VM Long Name_ghd_11.16.16","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7D410CC5-5E42-161E-E053-F662850AE1EA","beginDate":"2018-12-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-12-17","modifiedBy":"ONEDATA","dateModified":"2018-12-17","deletedIndicator":"No"},{"value":"NOS (T/B)","valueDescription":"Mixed Phenotype Acute Leukemia, B/T, Not Otherwise Specified","ValueMeaning":{"publicId":"6338189","version":"1","preferredName":"Mixed Phenotype Acute Leukemia, B/T, Not Otherwise Specified","longName":"6338189","preferredDefinition":"A very rare mixed phenotype acute leukemia, not otherwise specified in which the blasts show clear-cut evidence of both B-cell and T-cell lineage. (WHO 2017)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mixed Phenotype Acute Leukemia, B/T","conceptCode":"C151992","definition":"A very rare mixed phenotype acute leukemia in which the blasts show clear-cut evidence of both B-cell and T-cell lineage but are negative for KMT2A rearrangement and t(9;22)(q34;q11.2) translocation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6F2889D3-6AD1-431C-E053-F662850A5844","latestVersionIndicator":"Yes","beginDate":"2018-06-21","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-06-21","modifiedBy":"KUMMEROA","dateModified":"2023-12-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7D410CC5-5E57-161E-E053-F662850AE1EA","beginDate":"2018-12-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-12-17","modifiedBy":"ONEDATA","dateModified":"2018-12-17","deletedIndicator":"No"},{"value":"NOS (T/B/M)","valueDescription":"Mixed Phenotype Acute Leukemia, B/T/Myeloid, Not Otherwise Specified","ValueMeaning":{"publicId":"6338190","version":"1","preferredName":"Mixed Phenotype Acute Leukemia, B/T/Myeloid, Not Otherwise Specified","longName":"6338190","preferredDefinition":"A very rare mixed phenotype acute leukemia, not otherwise specified in which the blasts show evidence of trilineage (B-cell, T-cell, and myeloid lineage) assignment. (WHO 2017)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mixed Phenotype Acute Leukemia, B/T/Myeloid","conceptCode":"C151991","definition":"A very rare mixed phenotype acute leukemia in which the blasts show evidence of B-cell, T-cell, and myeloid lineage but are negative for KMT2A rearrangement and t(9;22)(q34;q11.2) translocation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6F2889D3-6AF6-431C-E053-F662850A5844","latestVersionIndicator":"Yes","beginDate":"2018-06-21","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-06-21","modifiedBy":"COOPERM","dateModified":"2018-12-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7D410CC5-5E6C-161E-E053-F662850AE1EA","beginDate":"2018-12-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-12-17","modifiedBy":"ONEDATA","dateModified":"2018-12-17","deletedIndicator":"No"},{"value":"B/M","valueDescription":"Mixed Phenotype Acute Leukemia, B/Myeloid, Not Otherwise Specified","ValueMeaning":{"publicId":"4538435","version":"1","preferredName":"Mixed Phenotype Acute Leukemia, B/Myeloid, Not Otherwise Specified","longName":"4538435","preferredDefinition":"A rare mixed phenotype acute leukemia in which the blasts express B-lymphoid and myeloid lineage markers but are negative for MLL translocation and t(9;22)(q34;q11.2) translocation.  The prognosis is usually unfavorable.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mixed Phenotype Acute Leukemia, B/Myeloid","conceptCode":"C82212","definition":"A rare mixed phenotype acute leukemia in which the blasts express B-lymphoid and myeloid lineage markers but are negative for KMT2A rearrangement and t(9;22)(q34;q11.2) translocation. The prognosis is usually unfavorable.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"058F579C-8D47-3DA1-E050-BB89AD436D0B","latestVersionIndicator":"Yes","beginDate":"2014-10-16","endDate":null,"createdBy":"WONGW","dateCreated":"2014-10-16","modifiedBy":"COOPERM","dateModified":"2018-12-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7D410CC5-5E81-161E-E053-F662850AE1EA","beginDate":"2018-12-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-12-17","modifiedBy":"ONEDATA","dateModified":"2018-12-17","deletedIndicator":"No"},{"value":"T/M","valueDescription":"Mixed Phenotype Acute Leukemia, T/Myeloid, Not Otherwise Specified","ValueMeaning":{"publicId":"4538437","version":"1","preferredName":"Mixed Phenotype Acute Leukemia, T/Myeloid, Not Otherwise Specified","longName":"4538437","preferredDefinition":"A rare mixed phenotype acute leukemia in which the blasts express T-lymphoid and myeloid lineage markers but are negative for MLL translocation and t(9;22)(q34;q11.2) translocation.  The prognosis is usually unfavorable.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mixed Phenotype Acute Leukemia, T/Myeloid","conceptCode":"C82213","definition":"A rare mixed phenotype acute leukemia in which the blasts express T-lymphoid and myeloid lineage markers but are negative for KMT2A rearrangement and t(9;22)(q34;q11.2) translocation. The prognosis is usually unfavorable.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"058F579C-8D6D-3DA1-E050-BB89AD436D0B","latestVersionIndicator":"Yes","beginDate":"2014-10-16","endDate":null,"createdBy":"WONGW","dateCreated":"2014-10-16","modifiedBy":"COOPERM","dateModified":"2018-12-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7D410CC5-5E95-161E-E053-F662850AE1EA","beginDate":"2018-12-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-12-17","modifiedBy":"ONEDATA","dateModified":"2018-12-17","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"TARGET:Therapeutically Applicable Research to Generate Effective Treatments","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7D410CC5-5DA7-161E-E053-F662850AE1EA","latestVersionIndicator":"Yes","beginDate":"2018-12-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-12-17","modifiedBy":"COOPERM","dateModified":"2019-01-16","changeDescription":"Created for ALAL CDE request 12.13.18 mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"5650570","version":"1","longName":"TARGET","context":"OCG","ClassificationSchemeItems":[{"publicId":"5650571","version":"1","longName":"ALL","context":"OCG"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"WHO RL1","type":"Preferred Question Text","description":"WHO RL1","url":null,"context":"OCG"}],"origin":"TARGET:Therapeutically Applicable Research to Generate Effective Treatments","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7D6866A0-2013-2171-E053-F662850A490D","latestVersionIndicator":"Yes","beginDate":"2018-12-19","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-12-19","modifiedBy":"COOPERM","dateModified":"2019-01-16","changeDescription":"Created for ALAL request 12.13.18 mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}